secwatch.observer — SEC 8-K summary
======================================

Issuer:     TuHURA Biosciences, Inc./NV (HURA)
CIK:        0001498382
Form:       8-K
Filed at:   2023-09-18T23:59:59+00:00
Accession:  0000950170-23-048593
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kintara Therapeutics FY2023 net loss $14.6M, cash $1.5M; VAL-083 data expected by year-end
--------------------------------------------------------------------------------

- Net loss $14.6M ($9.27/share) vs $22.7M ($25.80) in FY2022; R&D fell to $9.3M from $15.2M.
- Cash and equivalents $1.5M at June 30, 2023, down from $11.8M; working capital $188K.
- Awarded $2.0M NIH SBIR grant for REM-001; first patient in 15-patient study expected Q4 2023.
- Top-line data from VAL-083 GBM AGILE registrational study anticipated before end of calendar 2023.
- General and administrative costs decreased to $5.5M from $7.5M due to reduced staffing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1498382/000095017023048593/0000950170-23-048593-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1498382/000095017023048593/ktra-20230918.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-048593

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer